CHIP-IN-THE-PILL TECHNOLOGY

Metin Durakoğlu
2013712372
A pill that tells you when to take it

 Giant Swiss pharmaceutical company Novartis AG is

developing a pill containing an embedded microchip.
 The partnership with Proteus Biomedical, which
originally developed the technology, is one of several
alliances under development by Novartis.
 Working Principle
 When swallowed, activation of chips by
stomach acid
 About the size of a grain salt, the sensor
has no battery or antenna.
 Activation of sensor by wet stomach
juices
 Generating a tiny electric voltage for a
few minutes from copper and
magnesium coatings on the side of
sensor
Working Principle

Sending of data such as heart

rate, temperature and body
movements to a dermal patch
(worn on the patient’s torso
and event marker button must
be pressed manually at first)
via Bluetooth connectivity
 Working Principle
Transmition of signals by the aid of
electromagnetic radiation from patch to doctor
via smartphone or internet
The aim: Ensuring that patients took drugs at
the right time and got dose they needed.
Comments About The Technology
“We are taking forward this transplant
drug with a chip and we hope within
the next 18 months to have something
that we will be able to submit to the
regulators, at least in Europe. I see the
President of Global Health promise as going much beyond that.”

"The point of this technology

is not to say you are being a
bad patient. The point is to
have accurate data." Chief Medical Officer / Co-Founder
 Benefits Of The Technology

 Valuable feedback to healthcare providers for treatment

 Prevention of emergency situations
 Improving of health outcomes and providing cost reduction
 Small systems (1mm square and made of silicon) and pose
no risk to the patient when special controls are met
 Potential Applications
Core Metrics Why This Matters?
 Recovery (recover score  Provide accurate recovery
and sleep quality) assessment using heart rate
variability measurement
during sleep to minimize
external influences.
 Sleep (duration, start,  Provides context for recovery
stop) data.
 Provides accurate
measurement of resting heart
 Heart rate (resting and rate during sleep and
average heart rate) daytime.
 Other Related Information
 Novartis spent $24 million on securing access to
the ingestible medical microchips technology,
which was invented and developed by Proteus
Biomedical.
 Licensing the technology puts Novartis ahead of
all its competitors.
 The Proteus microchip is capable of collecting a
range of biometric data such as heart rate, body
temperature and body movements, which may
indicate if drugs are working as intended.
https://www.youtube.com/watch?v=-hhOtjdkU34